These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24142143)

  • 21. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey: author's reply.
    Oncel MY; Alyamaç-Dizdar E; Erdeve O; Oğuz S; Dilmen U
    Turk J Pediatr; 2013; 55(5):568. PubMed ID: 24401320
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
    Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
    Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
    Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L
    Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit.
    Alan S; Cakır U; Erdeve O; Atasay B; Arsan S
    Turk J Pediatr; 2013; 55(2):237-8. PubMed ID: 24192692
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
    Bollani L; Baraldi E; Chirico G; Dotta A; Lanari M; Del Vecchio A; Manzoni P; Boldrini A; Paolillo P; Di Fabio S; Orfeo L; Stronati M; Romagnoli C;
    Ital J Pediatr; 2015 Dec; 41():97. PubMed ID: 26670908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply.
    Oncel MY; Dizdar EA; Dilmen U
    Turk J Pediatr; 2013; 55(2):239. PubMed ID: 24205516
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
    Korbal P; Mikołajczak A; Szymański W
    Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants.
    Young J
    Respir Med; 2002 Apr; 96 Suppl B():S31-5. PubMed ID: 11996402
    [No Abstract]   [Full Text] [Related]  

  • 33. Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
    Hampp C; Kauf TL; Winterstein AG
    Value Health; 2010 Aug; 13(5):684. PubMed ID: 20412545
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective.
    Tulloh RM; Bury S
    Future Cardiol; 2014 Mar; 10(2):235-42. PubMed ID: 24762251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 36. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M; Rovers M; Sanders E; Bont L
    Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.